z-logo
open-access-imgOpen Access
HBP 1 promoter methylation augments the oncogenic β‐catenin to correlate with prognosis in NSCLC
Author(s) -
Tseng RuoChia,
Huang WayRen,
Lin SuFeng,
Wu PeiChen,
Hsu HanShui,
Wang YiChing
Publication year - 2014
Publication title -
journal of cellular and molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.44
H-Index - 130
eISSN - 1582-4934
pISSN - 1582-1838
DOI - 10.1111/jcmm.12318
Subject(s) - transactivation , cancer research , dna methylation , lung cancer , catenin , biology , gene silencing , immunohistochemistry , ectopic expression , gene knockdown , transcription factor , gene expression , medicine , gene , wnt signaling pathway , pathology , immunology , biochemistry
β‐catenin nuclear accumulation is frequently identified in human non‐small cell lung cancer ( NSCLC ). The HMG ‐box transcription factor 1 ( HBP 1) is a known repressor of β‐catenin transactivation. However, the role of HBP 1 in relation to β‐catenin nuclear accumulation has not been addressed in human cancer patients. In addition, the mechanism of HBP 1 gene alteration in NSCLC remains unclear, although HBP 1 mutation and gene deletion of HBP 1 are reported in breast and colon cancers. Here, we demonstrate that HBP 1 acts as a tumour suppressor and serves as a prognostic biomarker in NSCLC clinical and cell models. The immunohistochemistry data indicated that 30.5% (25/82) of tumours from NSCLC patients showed absence or low expression of HBP 1 protein. A significant inverse correlation between m RNA /protein expression and promoter hypermethylation suggested that promoter hypermethylation is responsible for low expression of HBP 1 in NSCLC patients. Reactivation of HBP 1 expression by demethylation reagent or ectopic expression of HBP 1 suppressed β‐catenin transactivation. Conversely, HBP 1 knockdown increased β‐catenin transactivation. Importantly, preserved expression of HBP 1 had a significantly protective effect on prognosis in patients with β‐catenin nuclear accumulation, suggesting that low expression of HBP 1 in NSCLC patients with β‐catenin nuclear accumulation was one of the major determinants of prognosis. Our data from cellular and clinical models suggest that HBP 1 is a suppressor of cancer progression, making it a potential prognostic predictor and therapeutic target to attenuate lung cancer progression.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here